News
-
MannKind Corporation has announced that a meeting of the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee for a review of the company’s NDA for Afrezza insulin inhalation powder has been scheduled tentatively for April 1,… Read more . . .
-
The FDA’s Nonprescription Drugs Advisory Committee and Pulmonary Allergy Drugs Advisory Committee (PADAC) will meet on February 25, 2014 to consider a new drug application submitted by Armstrong Pharmaceuticals for an OTC epinephrine inhalation aerosol… Read more . . .
-
Iliad Biotechnologies has licensed technology from Institut Pasteur de Lille, Inserm, National University of Singapore, and National University of Ireland Maynooth related to a live attenuated Bordetella pertussis vaccine, and the company says that it… Read more . . .
-
Civitas Therapeutics has announced the appointment of former MAP Pharmaceuticals CEO Timothy S. Nelson as Chairman of the board of directors. Nelson commented, “Civitas has a highly-validated drug inhalation platform, a potentially transformative Parkinson’s therapy… Read more . . .
-
Forest Laboratories has agreed to pay $2.9 billion cash for Aeroquin developer Aptalis. Aeroquin inhaled levofloxacin for the treatment of P. aeruginosa infections in CF patients, which is in Phase 3 development, was acquired by… Read more . . .
-
Aerogen and Philips have announced an agreement that “includes the acquisition of select assets solely related to Aerogen’s home-care business” by Philips. The announcement appears to refer to Aerogen’s Aeroneb Go vibrating mesh nebulizer. Philips… Read more . . .
-
Advocacy organization Allergy & Asthma Network Mothers of Asthmatics (AANMA) has announced that Tonya Winders will take over as Chief Executive Officer as of January 1, 2014. She succeeds founder Nancy Sander, who retired in… Read more . . .
-
The Food and Drug Administration is recruiting a postdoctoral fellow for a one year temporary position at the Division of Pharmaceutical Analysis in St. Louis, Missouri. The successful applicant will develop and carry out experimental… Read more . . .
-
Daiichi Sankyo has announced that Japanese regulators have approved its Inavir laninamivir octanoate hydrate DPI for the prevention of the flu. In August 2012, the company had announced positive Phase 3 results for that indication.… Read more . . .
-
Respira Therapeutics has announced that it will relocate to New Mexico after receiving new funding from Santa Fe-based Sun Mountain Capital and Cottonwood Technology Fund. The total amount of the investment from the venture capital… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA